SYSTEMIC SCLEROSIS: Choosing patients wisely when treating interstitial lung disease
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) requires accurate diagnosis and staging to identify patients with the highest risk of disease progression, who might benefit from treatment with immunosuppressants. New insights into predictors of mortality in patients with SSc-ILD should improve patient care and inform the design of future clinical trials.
Refers to Goh, N. S. et al. Short term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol.http://dx.doi.org/10.1002/art.40130 (2017)